Clinical Trial Update: A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer [Phase 1]

View source ↗

Summary

An update on a Phase 1 dose-escalation vaccine trial in HER2-overexpressing high-risk breast cancer patients. GlaxoSmithKline is sponsoring the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HER2-targeting vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 1 | Status: COMPLETED